Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity

Abstract

Predicting response to cancer immunotherapy is still a challenge. Here, the authors show that their method of predicting MHC-binding peptides, combined with profiling anti-immunogenic mutations, can better predict the clinical benefit of immunotherapy.